CM Life Sciences II Inc. (CMIIU)
Price:
11.22 USD
( - -0.64 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
CM Life Sciences II Inc. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses in the life sciences sector. The company was incorporated in 2020 and is based in New York, New York.
NEWS
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
globenewswire.com
2021-08-18 08:00:00BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers. The collaboration will allow Twist to use the SomaScan® Platform to quickly identify antibodies against targets resulting from SomaLogic's industry-leading 7,000-plex assay, believed to be one of the broadest views of the proteome available.
ARK Investment Leans Into Biotech and Telecom Holdings
gurufocus.com
2021-07-12 15:39:21Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available
businesswire.com
2021-07-06 08:01:00NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company's proteomics menu of 7,000 proteins. “Our customers have expressed a strong desire to use our platform to focus their work on smaller numbers of proteins of interest for drug discov
SomaLogic Latest to Take SPAC Route to Public Markets
gurufocus.com
2021-04-02 14:48:08SomaLogic is joining the growing number of companies going public via special purpose acquisition companies. The Boulder, Colorado-based health care company plans to merge with CM Life Sciences II Inc. (NASDAQ:CMIIU), whose lead entity is Casdin Capital LLC, a life-sciences investment group with $1.3 billion in assets under management.
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering
businesswire.com
2021-02-22 22:30:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “CMIIU” beginning February 23, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11
No data to display
No data to display
SomaLogic and Twist Bioscience Corporation announce partnership to discover novel therapeutic targets and antibodies
globenewswire.com
2021-08-18 08:00:00BOULDER, Colo. & SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- CM Life Sciences II (Nasdaq: CMIIU) and SomaLogic, Inc., a leader in AI-data driven proteomics technology, and Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced a collaboration aimed at creating novel antibodies and enabling innovative drug discovery based on key disease biomarkers. The collaboration will allow Twist to use the SomaScan® Platform to quickly identify antibodies against targets resulting from SomaLogic's industry-leading 7,000-plex assay, believed to be one of the broadest views of the proteome available.
ARK Investment Leans Into Biotech and Telecom Holdings
gurufocus.com
2021-07-12 15:39:21Catherine Wood (Trades, Portfolio)'s ARK Investment has revealed additions to three biotechnology and telecommunications holdings according to GuruFocus' Real-Time Picks, a Premium feature.
SomaLogic Customizable Protein Panels With Industry-Leading 7,000-Plex Assay Now Available
businesswire.com
2021-07-06 08:01:00NEW YORK & BOULDER, Colo.--(BUSINESS WIRE)--CM Life Sciences II (NASDAQ: CMIIU) and SomaLogic, Inc., a global leader in proteomics technology, announced today that their new customizable protein panel products are now available to pharma, biotechnology and academic research customers seeking the power of the company's proteomics menu of 7,000 proteins. “Our customers have expressed a strong desire to use our platform to focus their work on smaller numbers of proteins of interest for drug discov
SomaLogic Latest to Take SPAC Route to Public Markets
gurufocus.com
2021-04-02 14:48:08SomaLogic is joining the growing number of companies going public via special purpose acquisition companies. The Boulder, Colorado-based health care company plans to merge with CM Life Sciences II Inc. (NASDAQ:CMIIU), whose lead entity is Casdin Capital LLC, a life-sciences investment group with $1.3 billion in assets under management.
CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering
businesswire.com
2021-02-22 22:30:00NEW YORK--(BUSINESS WIRE)--CM Life Sciences II Inc. (the “Company”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol “CMIIU” beginning February 23, 2021. Each unit consists of one share of Class A common stock and one-fifth of one redeemable warrant, with each whole warrant exercisable to purchase one share of Class A common stock at a price of $11